Treatment of hepatitis C virus genotype 4 in the DAA era

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
ribavirin 7 infectiousdiseasesdrugs
ritonavir 3 infectiousdiseasesdrugs
hepatitis C 3 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ribavirin 6042 Genotype 4, SOF sofosbuvir, VEL velpatasvir, VOX voxilaprevir, LDV ledipasvir, SIM simeprevir, RBV ribavirin , EBR elbasvir, GZR grazoprevir, OBV ombitasvir, PTV paritaprevir, GLI glicaprevir, PIB pibrentasvir,
ribavirin 6305 open-label study at single center, 60 patients were enrolled and completed treatment with Sofosbuvir plus ribavirin for 12 weeks (31 patients) or 24 weeks (29 patients). SVR 12 was achieved by 21 of the 31 patients
ribavirin 7147 of patients who received 12 weeks of SOF/VEL, 16% of those who received 12 weeks of SOF/VEL plus ribavirin (RBV), and 18% of those who received 24 weeks of SOF/VEL. Only eight patients infected with GT4 have
ribavirin 13057 with cirrhosis treated for 24 weeks [[19]].Glecaprevir/pibrentasvirThe recently approved once-daily, ribavirin -free, DAA regimen of glecaprevir co-formulated with pibrentasvir, has been studied for pangenotypic
ribavirin 17723 triple therapy for 12 weeks and Group 2 (interferon ineligible) were treated with Sofosbuvir and ribavirin for 24 weeks. The study analysed the data from the first 14,409 patients who completed follow-up to
ribavirin 23156 recent multicenter trial investigated the efficacy and safety of OBV/PTV/r and dasabuvir with/without ribavirin in 35 GT1–4 HCV-infected patients undergoing hemodialysis [[37]]. In this difficult-to-treat population,
ribavirin 23416 relevant safety concern. The most relevant side effect was anemia, which was more marked in patients on ribavirin (n = 17) and requiring increase of the dose of erythropoiesis-stimulating agents. With specific reference
ritonavir 1159 patients was evaluated, favorable results are being derived from studies on ombitasvir/paritaprevir/ ritonavir , sofosbuvir and velpatasvir, whether or not in association with voxilaprevir, and with the new combined
ritonavir 11897 without RBV and the lowest, 0%, in patients treated for 16 weeks with RBV.Ombitasvir/paritaprevir/ ritonavir The efficacy of OBV/PTV/r in GT4 have also been explored in a multicentre phase 2b, randomised, open-label
ritonavir 19220 most cases, these events were likely due to RBV administration (e.g., anemia).Ombitasvir/paritaprevir/ ritonavir In addition to the above-mentioned experiences (see previous paragraph, [[25]–[28]]), in another ‘field-practice’
Select Disease Character Offset Disease Term Instance
hepatitis C 36 Title: Virology JournalTreatment of hepatitis C virus genotype 4 in the DAA eraAntonio Di BiagioLucia TaramassoGiovanni CenderelloPublication date (epub):
hepatitis C 455 effective in terms of sustained virological response (SVR) rates (> 90%) but also well tolerated in most hepatitis C virus (HCV) infected patients. Nevertheless HCV genotypes are different and only a small percentage
hepatitis C 1458 agents (DAAs) in clinical practice has undoubtedly represented a landmark advance in the treatment of hepatitis C virus infection (HCV) [[1], [2]]. With these therapies, the wide majority (90–95%) of HCV-infected

You must be authorized to submit a review.